Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Position Lifted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 22.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 497,362 shares of the company’s stock after acquiring an additional 91,152 shares during the period. Charles Schwab Investment Management Inc. owned about 0.70% of Zentalis Pharmaceuticals worth $1,507,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of ZNTL. Erste Asset Management GmbH acquired a new position in Zentalis Pharmaceuticals in the third quarter worth about $37,000. Paloma Partners Management Co acquired a new stake in Zentalis Pharmaceuticals during the third quarter valued at approximately $37,000. Ieq Capital LLC bought a new position in Zentalis Pharmaceuticals during the 4th quarter worth approximately $46,000. Capstone Investment Advisors LLC bought a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at approximately $48,000. Finally, Quarry LP bought a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at approximately $55,000.

Insider Activity at Zentalis Pharmaceuticals

In related news, insider Ingmar Bruns bought 20,000 shares of the stock in a transaction on Thursday, February 6th. The shares were purchased at an average price of $2.28 per share, with a total value of $45,600.00. Following the purchase, the insider now owns 36,629 shares in the company, valued at approximately $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jan Skvarka purchased 60,000 shares of the company’s stock in a transaction on Friday, January 31st. The shares were bought at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the transaction, the director now directly owns 149,551 shares in the company, valued at $257,227.72. This represents a 67.00 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Wells Fargo & Company decreased their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. UBS Group decreased their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Wedbush reiterated a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Trading Up 1.1 %

Shares of NASDAQ:ZNTL opened at $1.81 on Friday. The firm’s 50 day moving average is $2.04 and its two-hundred day moving average is $2.85. The firm has a market capitalization of $128.99 million, a P/E ratio of -0.73 and a beta of 1.75. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.61 and a 52 week high of $16.27.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Wednesday, March 26th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.09. The business had revenue of $26.90 million during the quarter. Analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.